Automated Lung Ultrasound Pulmonary Disease Quantification Using an Unsupervised Machine Learning Technique for COVID-19.

COVID-19 is an ongoing global health pandemic. Although COVID-19 can be diagnosed with various tests such as PCR, these tests do not establish pulmonary disease burden. Whereas point-of-care lung ultrasound (POCUS) can directly assess the severity of characteristic pulmonary findings of COVID-19, the advantage of using US is that it is inexpensive, portable, and widely available for use in many clinical settings. For automated assessment of pulmonary findings, we have developed an unsupervised learning technique termed the calculated lung ultrasound (CLU) index. The CLU can quantify various types of lung findings, such as A or B lines, consolidations, and pleural effusions, and it uses these findings to calculate a CLU index score, which is a quantitative measure of pulmonary disease burden. This is accomplished using an unsupervised, patient-specific approach that does not require training on a large dataset. The CLU was tested on 52 lung ultrasound examinations from several institutions. CLU demonstrated excellent concordance with radiologist findings in different pulmonary disease states. Given the global nature of COVID-19, the CLU would be useful for sonographers and physicians in resource-strapped areas with limited ultrasound training and diagnostic capacities for more accurate assessment of pulmonary status.